GeneSystem Co

GeneSystem Co Tax Expense

The Income Tax Expense of GeneSystem Co (363250.KQ) as of Nov 16, 2026 is -1.24 B KRW. In the previous year, Income Tax Expense was -150.73 M KRW — a change of 723.98% (lower).

Tax Expense

-1.24 BKRW

YoY

723.98%

Last updated:

Income Tax Expense of GeneSystem Co is 2025 -1.24 B KRW. Income Tax Expense of GeneSystem Co was 2024 -150.73 M KRW. It decreases by 723.98% lower compared to the previous year.

The GeneSystem Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
-1.37 B KRW
Jan 1, 2021
-386.59 M KRW
Jan 1, 2022
1.94 B KRW
Jan 1, 2023
146.41 M KRW
Jan 1, 2024
-150.73 M KRW
Jan 1, 2025
-1.24 B KRW
The GeneSystem Co Tax Expense history
YEARTax ExpenseYoY
-1.24 BKRW+723.98%
-150.73 MKRW-202.95%
146.41 MKRW-92.44%
1.94 BKRW-600.90%
-386.59 MKRW-71.74%
-1.37 BKRW—
0.00KRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Income Tax Expense of GeneSystem Co is -1.24 B KRW in 2025.

Income Tax Expense of GeneSystem Co changed from -150.73 M KRW to -1.24 B KRW, representing a 723.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GeneSystem Co

All Key Metrics — GeneSystem Co